It’s “In the News…” Got a few minutes? Get caught up!
Top stories this week include two big FDA approvals! Tandem’s Mobile Bolus and Eversense 180 day sensor both get the okay, we’re looking at earlier detection of T1D in kids, there’s a new discovery around a protein that might help T2D, info about Spare a Rose and Omnipod drops a hint about a crossover with a popular Nintendo game.
Join us LIVE every Wednesday at 4:30pm EST
Check out Stacey’s book: The World’s Worst Diabetes Mom!
Join the Diabetes Connections Facebook Group!
Sign up for our newsletter here
Use this link to get one free download and one free month of Audible, available to Diabetes Connections listeners!
Episode Transcription Below (or coming soon!)
Please visit our Sponsors & Partners – they help make the show possible!
Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and these are the top diabetes stories and headlines of the past seven days. If you’re new we go live on social media first and then All sources linked up at diabetes dash connections dot com when this airs as a podcast.
Looking to get organized? Diabetes supplies can really add up and all that pump and CGM stuff or even shots and wipes and strips can clutter everything up. I’ve got a great new guide to help you out. It’ll get you started and keep you organized. That’s totally free and it’s over on the podcast homepage.
Our top story this week – big movement from the US FDA, two approvals we’ve been waiting for. The first, Tandem Mobile bolus – what I’ve been calling bolus by phone. As expected, company says when released, this will be no additional cost for in-warranty customers through a remote software update. Limited launch in the spring, followed by expanded launch this summer. It’s compatible with both iOS and Android, although limited to just a couple of models right now. This is a very important step not just for customer convenicen but as Tandem moves forward with it’s new hardware line including Mobi will need an external device for full control.
The second FDA approval came through for The Eversense E3 continuous glucose monitor. This 180-day implantable sensor will be available later in 2022. If you’re not familiar, you have the sensor, inserted under the skin of the upper arm (and removed) every six months by a trained healthcare provider. There is a rechargeable transmitter which vibrates on the body for highs and lows.. and a mobile app. The sensor requires two calibrations per day for the first 21 days of wear. After that it requires one calibration. Lots of questions here and I’m talking to these folks for an upcoming episode.. look for that in about two weeks.
Saw an interesting post from Omnipod this week on IG.. All about Pat Podder® – the caption says she “is a long-time member of the Pod Squad who loves a good DIY project, going swimming, and to explore new places.” Take a look at this animation, along with the hashtag they used.. Animal Crossing.. are we about to see a gaming crossover? Insulet says an announcement is coming Thursday of this week, so if you’re listening to the podcast it may have already happened.. I’ll follow up.
Big push in Germany to get doctors to screen very young kids for type 1. This group conducted the world’s largest population based screening for type 1 diabetes in children so far. Since 2015, any child aged 2–5 years in Bavaria, Germany, could have their blood tested for islet autoantibodies. These show early stage type 1 diabetes years before high blood sugars and other symptoms. More than 90-thousand kids have been tested and point 31 percent (.31%) have been diagnosed. Next up is to take a deep dive into the potential cost savings and increased quality of life compared to what happens without these early screenings.
It’s a mouse study.. but good potential here for a drug to treat type 2 diabetes. It works by amplifying a protein that has a positive effect on insulin. The protein is called Swell-1 and it’s vital for normal insulin secretion from pancreatic cells. And, SWELL-1 activity seems to be significantly disrupted in people with type 2. Fixing that seems to restore both insulin sensitivity and insulin secretion. And it does this without lowering blood glucose when that’s not needed. Long way to go but promising..
The Spare a Rose campaign was back – focusing on Valentine’s Day but continuing through February. The idea here is that instead of buying a dozen roses.. you buy 11 and donate the value of that last flower to help someone with diabetes. Since starting in 2013 Spare a Rose has raised almost 400-thousand dollars.. most of that has gone to Life for A Child. Now, these donations are going to the Insulin For Life Global organization. It provides insulin, supplies, education, and advocacy to children and adults. With that the name has changed from Spare a Rose, save a child to Spare a Rose save a life.
More type 1 at the Olympics! Last week we told you about Snow Boarder Kamilla Kozuback who was diagnosed at age 13. Czech skeleton athlete Anna Fernstädtová came in 7th a couple of days ago. A MONTH ago she was in the hospital, newly diagnosed with diabetes. She wrote on Instagram: “7th place at the Olympic Games. Not the runs I wanted, not the result I wanted. But these are happy tears. Not even a month ago I was in hospital, without knowing what would happen. But we made it happen. Thank you everyone who got me here And to everyone who is also dealing with type 1 diabetes: everything is possible! You got this!!”
Our long format episode this week is with the folks at Sigi pump.. a new tubeless rechargeable pump that got breakthrough device designation last fall.
Listen wherever you get your podcasts
That’s In the News for this week.. if you like it, please share it! Thanks for joining me! See you back here soon.